| Literature DB >> 27181992 |
Jennifer A Juno1, Jillian L M Waruk2, Christine Mesa2, Carmen Lopez3, Joe Bueti4, T Blake Ball5, Sandra A Kiazyk5.
Abstract
End-stage renal disease (ESRD) patients exhibit elevated risk of tuberculosis (TB) reactivation, but current diagnostics, including the interferon gamma release assay (IGRA), exhibit poor sensitivity in ESRD. We tested 80 ESRD patients and found an 18.75% prevalence of IGRA positivity. A subset of patients was assessed for Mtb-specific expression of 44 cytokines/chemokines, and CD4+ T cell phenotype and function. Similar to non-ESRD IGRA+ individuals, Mtb-specific IFNγ, IL-1RA, IP-10, MCP-3 and IL-2 responses were identified in the ESRD IGRA+ group. 27% of the ESRD IGRA- group exhibited MCP-3 or IL-2 Mtb-specific responses, which may identify cases of latent TB infection in ESRD. Stimulation of PBMC with PPD demonstrated similar CD4+ T cell production of IFNγ, TNFα and GM-CSF by ESRD patients. The reported low sensitivity of the IGRA in ESRD cohorts is therefore unlikely to be due to poor T cell cytokine secretion, and may instead reflect defects in antigen presentation.Entities:
Keywords: Diabetes; ESRD; IGRA; MCP-3; TB
Mesh:
Substances:
Year: 2016 PMID: 27181992 DOI: 10.1016/j.clim.2016.05.004
Source DB: PubMed Journal: Clin Immunol ISSN: 1521-6616 Impact factor: 3.969